Kevinkd123-123_123

The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030

An analysis of the various partnerships pertaining to non-invasive cancer diagnostics

January 28, 2021

Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers,

The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across

January 28, 2021

The non-invasive cancer diagnostics market is projected to grow at an annualized rate of ~20%, till 2030

Presently, nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world

January 28, 2021

The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion by 2030, predicts Roots Analysis

An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019.

January 28, 2021

The “Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030”

A detailed discussion on the cost implications across various steps of the HFE and usability testing process.

January 28, 2021

More than 90 companies claim to offer human factors engineering and usability testing services,

Human factors engineering and usability testing have now become an essential part of product design across almost all industries

January 28, 2021

The human factors engineering and usability testing service market is projected to grow at an annualized rate of ~14%, till 2030

Players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and gain an advantage over competitor firms

January 28, 2021

The human factors engineering and usability testing services market for medical devices is projected

Based on the revenues generated from different services for usability testing, currently, the maximum share is expected to be generated through evaluative testing methodologies (61%), followed by generative testing methodologies (39%).

January 28, 2021

The “China Biopharmaceutical Contract Manufacturing Market, 2020-2030”

A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes

January 27, 2021

Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products

In order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives

January 27, 2021

The Chines biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~13%, till 2030

Big pharma players have also made significant investments in this region, including establishing new facilities, expanding existing R&D centers and growing manufacturing facilities, focused on biotherapeutics

January 27, 2021

The Chinese biopharmaceutical contract manufacturing market is estimated to be worth USD 2.6 billion in 2030

An analysis of the initiatives of big biopharma players engaged in this domain.

January 27, 2021

The “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030”

A discussion on the upcoming opportunities (such as development of companion diagnostics, emerging technologies for biomarker assessment, and others) that are likely to impact the evolution of this market over the coming years

January 27, 2021

Presently, close to 50 companies are offering a variety of analytical testing solutions for the assessment of novel cancer biomarkers

Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.

January 27, 2021

Cancer biomarkers market for TMB, MSI / MMR and TILs is projected to grow at an annualized rate of ~18%, till 2030

Several novel biomarkers are presently under investigation for a variety of cancer indications; the initiatives of big pharmaceutical companies are indicative of the growing interest in this domain

January 27, 2021

The “Neoantigen Targeted Therapies Market, 2019-2030”

An analysis of the investments made, including seed financing, venture capital financing

January 25, 2021

Presently, over 150 neoantigen targeted therapies are being evaluated for advanced cancer indications

Several therapy candidates are being investigated both as monotherapies and in combination

January 25, 2021

The neoantigen targeted therapies market is projected to grow at an annualized rate of 57%, till 2030

Presently, over 150 neoantigen targeted therapies are being evaluated for advanced cancer indications and are designed for delivery via different routes of administration

January 25, 2021

The neoantigen targeted therapies market is estimated to be worth USD 3 Billion in 2030, predicts Roots Analysis

An in-depth analysis of the various patents that have been filed / granted related to neoantigens.

January 25, 2021

Neoantigen targeted therapies market projected to reach USD 3 Billion by 2030, growing at an annualized rate of 57%, claims Roots Analysis

n fact, more than 6,000 patents were filed / granted related to neoantigen targeted therapies, since 1978.

January 25, 2021

The ‘Contract Regulatory Affairs Management Market for Medical Devices, 2019-2030’

 A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing regulatory affairs management services to medical device developers

January 25, 2021

Over 400 companies claim to possess the required expertise to offer regulatory affairs management-related services

More than 130 medical devices were approved by the FDA since January 2018

January 25, 2021

The contract regulatory affairs-management services market for medical devices is estimated to be worth USD 820 million by 2030,

The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of such firms are located in the developed geographies

January 25, 2021

The contract regulatory affairs-management services market for medical devices is estimated to be worth USD 820 million by 2030

Over the years, outsourcing has become a popular trend with the medical device industry, allowing innovators to leverage the technical and regulatory expertise of contract service providers in order to expedite time to market

January 25, 2021

The In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules

A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules

January 15, 2021

Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics

Presently, in silico tools / approaches are available for the identification

January 15, 2021

In silico drug discovery services market is likely to be worth USD 124 million by 2030

Majority of the companies offer structure-based drug design focused on early stage drug discovery of a range of large molecules, including antibodies, proteins and peptides

January 15, 2021

In silico drug discovery services market is likely to be worth USD 124 million by 2030

A detailed assessment of the current market landscape of companies offering in silico drug discovery services for large molecules.

January 15, 2021

The “Global Handheld Ultrasound Imaging Devices Market, 2020-2030”

A detailed brand positioning analysis of key industry players, highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects

January 15, 2021

In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at an annualized rate of 15.6%, claims Roots Analysis

Over 150 software solutions are currently available for use in drug discovery

January 15, 2021

Several players are currently engaged in the development / manufacturing over 100 point-of-care handheld ultrasound scanners

According to industry experts, handheld ultrasound imaging devices are being adopted at a faster pace by different end-users owing to their higher efficiency and wider applicability.

January 15, 2021

The global handheld ultrasound imaging devices market is projected to be over USD 1.1 billion by 2030

Around 100 handheld ultrasound imaging devices, incorporating different transducer arrays and advanced software, are being actively used by physicians to scan different body parts.

January 15, 2021

The global handheld ultrasound imaging devices market is projected to be over USD 1.1 billion by 2030

A detailed assessment of the current market landscape of companies engaged in the development / manufacturing of handheld ultrasound imaging devices

January 15, 2021

The global handheld ultrasound imaging devices market is projected to be over USD 1.1 billion by 2030, growing at a CAGR of 11%, claims Roots Analysis

According to industry experts, handheld ultrasound imaging devices are being adopted at a faster pace by different end-users owing to their higher efficiency and wider applicability.

January 15, 2021

The ‘‘Microbial Contract Biomanufacturing Market, 2020-2030’’

A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

January 14, 2021

Over 115 companies, across the world, claim to offer a variety of product development

Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.

January 14, 2021

The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%, till 2030

The market features the presence of several well-established players across the globe

January 14, 2021

The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030, predicts Roots Analysis

Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs

January 14, 2021

The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030, growing at a CAGR of 8.7%, claims Roots Analysis

The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment

January 14, 2021

The “In Vitro ADME Testing Services Market, 2019-2030”

A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2005-2018

January 14, 2021

Over 90 firms are actively involved in providing in vitro ADME testing services; of these,

Currently, there are a number of contract research organizations (CROs) that claim to have the necessary capabilities to offer in vitro ADME services.

January 14, 2021

In vitro ADME testing services market is likely to be worth USD 2.2 billion by 2030, growing at an annualized rate of ~9.8%

Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective in the in vitro

January 14, 2021

In vitro ADME testing services market is likely to be worth USD 2.2 billion by 2030, growing at an annualized rate of ~9.8%, predicts Roots Analysis

Nearly 60% of these companies are small and mid-sized firms. Further, close to 35% of the CROs engaged in this domain, claim to provide services to both pharmaceutical companies and academic institutes.

January 14, 2021

Kevinkd123-123_123 · Newsroom